GlassScriptPhysician profile
Bruce G Dains
NPI 1013007285
$2,347.29
in general payments reported to CMS, 2019-2025
20 companies · $20.98 in 2025
The $20.98 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,306 · 2022: $20.71 · 2025: $20.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $412.89 | 2021 | |
| Novo Nordisk INC | $311.00 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $295.08 | 2021 | |
| Sanofi-Aventis U.S. LLC | $209.75 | 2021 | |
| Lilly USA, LLC | $187.29 | 2021 | |
| Merck Sharp & Dohme LLC | $185.88 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.88 | 2021 | |
| Vistapharm, INC. | $155.34 | 2021 | |
| Abbvie INC. | $67.63 | 2021 | |
| Medtronic, INC. | $63.46 | 2021 | |
| Insulet Corporation | $41.24 | 2021 | |
| Corcept Therapeutics | $35.42 | 2021 | |
| Amarin Pharma, INC. | $33.26 | 2021 | |
| Dexcom, INC. | $31.50 | 2021 | |
| Zealand Pharma US, INC. | $24.48 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $23.78 | 2021 | |
| Ascensia Diabetes Care US INC. | $23.41 | 2021 | |
| Ibsa Pharma INC. | $22.68 | 2021 | |
| Electronic Waveform Lab, INC. | $20.98 | 2025 | |
| Abbott Laboratories | $18.34 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Dains listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.